Pfizer, BioNTech to develop mRNA-based vaccines for influenza
Under the deal, the partnership will carry out research and development activities for the advancement of mRNA-based flu vaccines. BioNTech co-founder and CEO Dr Ugur Sahin said: “Today’s
ACROBiosystems has upgraded its global licence solution for HEK293 functional cell lines, aimed at streamlining compliance to expedite biopharmaceutical research and development (R&D).